🚨 We’re looking for an Academic Clinical Fellow in Urology ST1/2 level. An exciting opportunity to join the University of Cambridge, contribute to cutting-edge research + develop your clinical career. 📍Cambridge 🗓️ Applications open now via Oriel: 👉 lnkd.in/eUJgPwC9

The third blog in our series on INKCC is out now: recommendations for assessing pathological response in neoadjuvant kidney cancer trials Read more 👇 www.cambridge-urologicalmalignancies.org.uk/post/towards...

🚨 New blog: Our researchers publish new data demonstrating the prevalence of kidney cancer in high-risk individuals, using data from our @yorkshirecancer.bsky.social funded kidney screening trial. Read more 👉 www.cambridge-urologicalmalignancies.org.uk/post/urologi...

We've just shared the second blog in our series about the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC), a group of experts building strategy in research on neoadjuvant therapies for patients with kidney cancer: www.cambridge-urologicalmalignancies.org.uk/post/finding...

Congratulations to Harveer and Simon on publishing outcomes from their CANCAP03 trial

Congratulations our own Tom Mitchell on winning the Christopher G Wood Rising Star Award at #IKCSEU2025 earlier this month - very well deserved!

New analysis by Sheffield Centre for Health and Related Research in collaboration with UMVI researchers, using data from our world-first Yorkshire Kidney Screening Trial, shows that screening for kidney cancer is potentially cost effective. Read more: doi.org/10.1038/s414... (1/6)

Rebecca Wray, joint first author on this paper, presented her work at the @theaacr.bsky.social Annual Meeting this weekend

Using a machine learning model to analyse data from the NAXIVA trial, @crukcamurol.bsky.social members have discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus using a drug called axitinib. Read more: crukcambridgecentre.org.uk/news/researc...

New work led by James Jones, published this week in @natcomms.nature.com, has discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus (VTT) using a drug called axitinib. crukcambridgecentre.org.uk/news/researc...